江 巍,白盟盟,王海峰,贺 兰,赵 杰.左甲状腺素联合碘131对甲状腺功能亢进症患者甲状腺体积、TR-Ab和TPOAb水平的影响[J].,2020,(7):1305-1308 |
左甲状腺素联合碘131对甲状腺功能亢进症患者甲状腺体积、TR-Ab和TPOAb水平的影响 |
Effects of Levothyroxine Combined with Iodine 131 on Thyroid Volume, TR-Ab and TPOAb Levels in Patients with Hyperthyroidism |
投稿时间:2019-11-01 修订日期:2019-11-26 |
DOI:10.13241/j.cnki.pmb.2020.07.022 |
中文关键词: 左甲状腺素 碘131 甲状腺功能亢进症 甲状腺体积 促甲状腺激素受体抗体 甲状腺过氧化物酶抗体 |
英文关键词: Levothyroxine Iodine 131 Hyperthyroidism Thyroid volume Thyrotropin receptor antibody Thyroperoxidase antibody |
基金项目:内蒙古自治区自然科学基金项目(2017MS(LH)0848) |
|
摘要点击次数: 1022 |
全文下载次数: 519 |
中文摘要: |
摘要 目的:研究左甲状腺素联合碘131对甲状腺功能亢进症患者甲状腺体积、促甲状腺激素受体抗体(Thyrotropin receptor antibody,TR-Ab)和甲状腺过氧化物酶抗体(Thyroid peroxidase antibody,TPOAb)水平的影响。方法:选择2013年1月-2019年1月我院收治的68例甲状腺功能亢进症患者,随机分为两组。对照组使用小剂量(111~148 MBq)的碘131,观察组在碘131的基础上,联合服用左甲状腺素,每次12.5 μg,每日1次,均治疗3个月后观察疗效及甲状腺体积、TR-Ab和TPOAb水平变化。结果:观察组治疗3个月后的有效率明显高于对照组(P<0.05);治疗前,两组的甲状腺体积、TR-Ab和TPOAb水平无明显差异(P>0.05),治疗后,两组的上述指标均明显降低(P<0.05),且观察组明显低于对照组(P<0.05);治疗前,两组的血清游离三碘甲状腺原氨酸(Free triiodothyronine,FT3)、促甲状腺素(Thyroxine,TSH)和游离四碘甲状腺素(Free tetraiodothyroxine,FT4)水平无明显差异(P>0.05),治疗后,两组的血清 FT3和FT4水平明显降低(P<0.05),血清TSH水平明显升高(P<0.05),观察组更加明显(P<0.05);治疗前,两组的血清甲状腺球蛋白(Thyroglobulin,Tg)和 半胱氨酸蛋白酶抑制剂 C(Cysteine protease inhibitor C,Cys C)水平无明显差异(P>0.05),治疗后,两组的血清Tg和 Cys C水平明显降低(P<0.05),观察组明显低于对照组(P<0.05)。结论:左甲状腺素联合碘131对甲状腺功能亢进症有确切的疗效,能有效阻碍甲状腺自身抗体产生,改善甲状腺功能,降低血清Tg和 Cys C水平。 |
英文摘要: |
ABSTRACT Objective: To study the effect of levothyroxine combined with iodine 131 on thyroid volume, thyrotropin receptor antibody and thyroid peroxidase antibody levels in patients with hyperthyroidism. Methods: Sixty-eight patients with hyperthyroidism who were admitted to our hospital from January 2013 to January 2019 were randomly divided into two groups. The control group used a small dose (111-148 MBq) of iodine 131, and the observation group based on iodine 131 in combination with levothyroxine, 12.5 μg each time, once a day, both observed the efficacy and thyroid after 3 months of treatment Volume, TR-Ab, and TPOAb levels changed. Results: The effective rate of the observation group after 3 months of treatment was significantly higher than that of the control group (P<0.05). Before treatment, there was no significant difference in thyroid volume, TR-Ab and TPOAb levels between the two groups (P>0.05). After treatment, the thyroid volume, TR-Ab and TPOAb levels of the two groups decreased significantly (P<0.05), while the thyroid volume, TR-Ab and TPOAb levels of the observation group were significantly lower than those of the control group (P<0.05). Before treatment, there was no significant difference in serum FT3, TSH and FT4 levels between the two groups (P>0.05). After treatment, the serum FT3 and FT4 levels of the two groups decreased significantly (P<0.05), and the serum TSH levels increased significantly (P<0.05), especially in the observation group (P<0.05). Before treatment, there was no significant difference in serum Tg and C ys C levels between the two groups (P>0.05). After treatment, the serum Tg and Cys C levels of the two groups decreased significantly (P<0.05), while the serum Tg and Cys C levels of the observation group were significantly lower than those of the control group (P<0.05). Conclusion: Levothyroxine combined with iodine 131 has definite curative effect on hyperthyroidism. It can effectively block the production of thyroid autoantibodies, improve thyroid function and reduce serum Tg and C ys C levels. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|